In the neurodegeneration-multiple disease pathway which contained 29 MFS-AD-treating targets, most targets were associated with serine/threonine–protein kinase and G-protein coupled receptors, including MAPK3 (Figure 6D). Here, MAPK3 is linked to Alzheimer disease.